Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047425 | 0.86 | MAPT (0.62) | HTR2APOLBGAAHTTMAPT | |
| SCHEMBL3048697 | 0.86 | CCR5 (0.70) | HTR2ACCR5HTR6KMT2A | |
| SCHEMBL3038901 | 0.85 | RAB9A (0.60) | HTR2APOLBCCR5GAAHTT | |
| SCHEMBL3047069 | 0.83 | POLB (0.57) | POLBGAAHTTMAPTKDM4E | |
| SCHEMBL3047421 | 0.79 | POLB (0.60) | POLBHTR6HTTHRH3KDM4E | |
| SCHEMBL3052139 | 0.77 | CCR5 (0.57) | HTR2ACCR5HTR6MEN1KMT2A | |
| SCHEMBL15134818 | 0.77 | HRH3 (0.71) | POLBGAAHRH3MEN1KMT2A | |
| SCHEMBL254551 | 0.75 | ALDH1A1 (0.63) | HTR2APOLBGAAMAPTMEN1 | |
| SCHEMBL2404203 | 0.75 | CCR5 (0.65) | CCR5HRH3L3MBTL1 | |
| SCHEMBL2056172 | 0.74 | HTR2A (0.62) | HTR2ACCR5HTR6GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | claimed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | HRH3, HRH4, HRH2 | HTR2A 34/4885POLB 3476/4885CCR5 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.